TABLE 2.

Phenotypic and genotypic properties of 41 MRSA isolates belonging to minor clones or sporadic isolates present in hospitals

Country and strainYr of isolationAntibiogramaClonal typespaA typeSTMLSTCCbSCCmec typecccr typemec complexluk-PVdDoubling time (min)eSource or reference
PENOXAERYGENCLICHLCIPRIFTETSXTVAN
Portugal
    HSA101992RRRRRSSSRSSIII::α::AWGKAOM2392-3-1-1-4-4-38NT-III3A32.855
    HSA491993RRSRSSRSSSSV::NH::BTJMBMDMGMK51-4-1-4-12-1-105IV2B25.965
    HGSA91997RRRRSSRISRSXI::B::gNontypeable2392-3-1-1-4-4-38IIIA26.625
    HGSA1282000RRRSSSRSSSSXI::NH::D1TJJEJNI2MNI2MOMOKR797-6-1-33-8-8-622IV2B25.025
    IPOP22001RRRSSSRSSSSII::NA::D2TJJEJNI2MN12MOMOKR227-6-1-5-8-8-622IV2B29.12This study
Italy
    ITL2621997RRSRSSRRRSSII::NH::EYHFGFMBQBLO2473-3-1-12-4-4-168I26.97-f
    ITL5921998RRRRRSRRSSSII::E::FTIMBMDMBMDMGMK2281-4-1-4-12-24-295I34.66-
    ITL1131997RRRRRRRRSSSII::E::GTIMBMBMDMGMK2281-4-1-4-12-24-295I30.94-
Turkey
    TUR41996RRIRSSRRRSSII::ηη::HWGKAQQ2392-3-1-1-4-4-38III29.62This study
    TUR91995RRRRRSRRRSSIII::A::I2WGKAQQ2392-3-1-1-4-4-38III31.65This study
    TUR11996RRRRSRRRRSSIII::A::JWGKAQQ2392-3-1-1-4-4-38III27.84This study
    TUR271996RRRRSSRRRSSII::D::IIWGKAQQ2392-3-1-1-4-4-38III30.01This study
Greece
    GRE141998RRSSRSSSSSSII::NH::KUJGBBPB801-3-1-14-11-51-10SIV2B+26.561
    GRE1201993RRRRSSSSRRSII::E::LYGFMBQBLPO83-3-1-1-4-4-38IV2B30.271
    GRE1081998RRRRRSSRRRSIII::B::MXKAOMMQ2392-3-1-1-4-4-38III32.241
Czech Republic
    CR11996RRSSSRSSSSSII::NH::NYGFMBQBLO83-3-1-1-4-4-38IV2B25.6723
    CR431996RRRRRRSSRSSI::NH::OYHGFMBQBLO83-3-1-1-4-4-38IV2B33.8123
Poland (PLN49)1997RRSSSSSSRSSII::NH::PXKAKBEMBKB4510-14-8-6-10-3-245IV2B27.1820
Chile
    CHL51997RRRRRRRSSRSII::E′::Q2TMK831-4-1-4-12-1-15I33.324
    CHL631997RRRRRRRIISSII::E::Q1TIMEMDMGMGMK51-4-1-4-12-1-105I31.224
Colombia (COB111)1998RRRSSSRSSSSII::NH::RJCMBPB841-26-28-32-18-33-2791IV2B30.8118
Argentina
    ARG331996RRRRSRRRSSSII::E::STIMBMDMGMK8531-4-1-4-12-1-105IIIA31.947
    ARG1271995RRSRSSSSSSSII::NH::TWGKAKAOMQQ302-2-2-2-6-3-230IVA2B34.157
    ARG2291995RRSRSSSSSSSI::NH::UTJMBMDMGMK1001-65-1-4-12-1-105IV-new12None30.677
    ARG1991996RRRSSSSSSSSI::NH::VUJGFGMDMGGM862-4-1-8-4-4-38IVA-new12None28.187
    ARG641996RRRRSRRRRRSII::EE::XTIMBMDMGMK8531-4-1-4-12-1-105I35.917
ARG1051995RRRRSSRIRSSII::E::WIYHFGFMBQBLO2473-3-1-12-4-4-168IV-new2NoneNone35.017
    AGT421996RRRRRRRRSSSIX::OO::YTIMBMDMGMK51-4-1-4-12-1-105I30.544
    AGT301996RRRRRSRRRSSXI::E::W2YHFGFMBQBLO2473-3-1-12-4-4-168IV-new2NoneNone30.544
    AGT551996RRRRSSSRSSSIX::E::aUMDJMGMK51-4-1-4-12-1-105I28.184
Brazil
    BZ401996RRRRRSSRSRSI::E::Z1TMK51-4-1-4-12-1-105I29.624
    BZ481997RRRRRRRSRRSIII::B::C1Nontypeable2392-3-1-1-4-4-38IIIA34.314
    BZ141996RRIRSSSRSRSII::E::Z1TMK51-4-1-4-12-1-105I29.754
Japan
    JP841997RRRSSSRSSSSI::J::bYHHGFMBQQBLO83-3-1-1-4-4-38I27.513
    JP821997RRSRSSSSSSSI′::NH::cEJCMBPB921-26-28-18-18-54-2791IVA2B28.643
    JP871997RRRSRSSSSSSI::A::dEJCMBPB891-26-28-18-18-33-5091II′2A27.953
    JP261997RRRSRSRSSSSI::A::eTJMBMDMGMK51-4-1-4-12-1-105II24.933
    JP2381998RRRRSSISSSSI::A::fTDMGMK51-4-1-4-12-1-105II′′2A27.843
Taiwan
    TAW971998RRRRRRRRRRSXI::B::C2WGKAOMQ2392-3-1-1-4-4-38IIIA34.482
    TAW2141998RRRRRRSSSSSII::NH::hZDMDMOB5919-23-15-2-19-20-15SIV2B28.412
    TAW1661998RRRRRRSRRSSII::ZZ::jNontypeable813-32-1-1-4-4-38NT-IV2B34.312
  • a Antibiotic abbreviations: PEN, penicillin; OXA, oxacillin; ERY, erythromycin; GEN, gentamicin; CLI, clindamycin; CHL, chloramphenicol; CIP, ciprofloxacin; RIF, rifampin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin. A few isolates were tested for fusidic acid and teicoplanin resistance. R, resistant, S, susceptible; I, intermediate.

  • b Based on BURST. S, singleton (not assigned to any clonal complex).

  • c NT, isolate considered nontypeable by the multiplex strategy due to extra or missing amplification fragments relatively to the described patterns.

  • d luk-PV genes encode PVL. +, presence of PVL determinant; −, absence of PVL determinant.

  • e Doubling time during exponential growth phase.

  • f -, R. Mato et al., unpublished data.